Stoke Therapeutics, Inc. Payments of Financing Costs
Stoke Therapeutics, Inc. (STOK) reported Payments of Financing Costs of $179.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-10.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2022-03-10
- Stoke Therapeutics, Inc. payments of financing costs for the quarter ending 2020-12-31 was -$181.00K.
- Stoke Therapeutics, Inc. payments of financing costs for the quarter ending 2019-03-31 was $141.00K.
- Stoke Therapeutics, Inc. payments of financing costs for fiscal 2020 was $179.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|
| 2020-12-31 | -$181.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $179.00K 10-K · filed 2022-03-10 | |
| 2020-09-30 | $360.00K 10-Q · filed 2021-11-08 | ||
| 2019-03-31 | $141.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |